Loading
Inogen Inc Stock: price and insider trades · United States
Inogen Inc: what insiders have been doing
Inogen Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Inogen Inc logged 16 filings by 8 insiders.
Only sales appear on the open market, 1 sale in all totalling €63k, filed by 1 insider. Biggest ticket of the year: €63k, sold by Yi Boyer Jennifer M and made public on 6 July 2026 (0.053% of market cap).
Compared with its exchange (5,816 companies, median 19 filings), a count of 16 filings is below the norm. The full history, which starts in 2016, counts no purchases against 6 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 348.7 m USD and net income of -22.7 m USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
123
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€32M
6 ops. · all time
Who traded when
BuySaleBoyer Jennifer M. Yi1 sale
Analyst consensus: bullish or bearish?
Analysts rate Inogen Inc Strong Buy (bullish), based on 2 analysts. Average price target: US$12.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,589 of 24,148 companies
22.8
score / 100
Value14
Quality32
FCF yld-13%
Earn yld-14%
EV/EBITDA·
ROE-13%
Gross mgn44%
Net mgn-6.5%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$6.34
Analyst consensus
2 analystsStrong buy
US$12.00Target US$12.00(+89%)US$12.00
Income statement
RevenueUS$348.7M
Gross profitUS$154.3M44% margin
EBITDA-US$9.5M-3% margin
Net income-US$22.7M-6.9% margin
Valuation
PER (forward)-39.6x
P/Book1.0x
Beta1.50
Balance sheet & cash
Market capUS$168.3M
Total debtUS$17.5M
Free Cash Flow-US$21.6M
Debt / Equity9%
Profitability & ownership
ROE-13.1%
ROA-5.8%
% insiders12.9%
% institutions80.3%
Last declaration on 3 September 2026
Declarations123 total
1,500 shares@ US$5.330.0058% mcap21.1% of flowCommon StockSEC:0001802639-26-000004:0
1,500 shares@ US$5.330.0058% mcap9.3% of flowCommon StockSEC:0002031211-26-000004:0
8,671 shares@ US$5.330.034% mcap53.7% of flowCommon StockSEC:0002031211-26-000004:2
18,136 shares0Common StockSEC:0002031211-26-000004:1
1,500 shares@ US$5.330.0058% mcap47.0% of flowCommon StockSEC:0002079955-26-000003:0
10,938 shares@ US$6.59590.053% mcap100.0% of flowCommon StockSEC:0002079957-26-000006:0
10,938 shares@ US$6.450.052% mcap100.0% of flowCommonSEC144:0001950047-26-006735
28,081 shares0Common StockSEC:0001670936-26-000004:0
685 shares@ US$6.1010.8% of flowCommon StockSEC:0001193125-26-088582:0
1,500 shares@ US$6.1010.5% of flowCommon StockSEC:0001193125-26-088591:0
874 shares@ US$6.1023.1% of flowCommon StockSEC:0001193125-26-088586:0
1,500 shares@ US$6.1053.0% of flowCommon StockSEC:0001193125-26-088630:0
4,680 shares0Common StockSEC:0001193125-26-088606:0
13,005 shares0Common StockSEC:0001193125-26-088594:0
31,566 shares0Common StockSEC:0001193125-25-305257:0
28,334 shares0Common StockSEC:0001193125-25-305251:0
1,500 shares@ US$7.9952.3% of flowCommon StockSEC:0001638420-25-000004:0
1,500 shares@ US$7.9913.8% of flowCommon StockSEC:0002031211-25-000005:0
1,500 shares@ US$7.9931.3% of flowCommon StockSEC:0001802639-25-000004:0
30,612 shares0Common StockSEC:0000950170-25-073975:0
30,612 shares0Common StockSEC:0000950170-25-073841:0
30,612 shares0Common StockSEC:0000950170-25-073842:0
30,612 shares0Common StockSEC:0000950170-25-073845:0
30,612 shares0Common StockSEC:0000950170-25-073843:0
30,612 shares0Common StockSEC:0000950170-25-073844:0
25 of 123 declarations
About Inogen Inc
Inogen Inc. (Nasdaq: INGN) is a U.S.-based medical technology company focused on respiratory care for the homecare setting. Headquartered in Goleta, California, and listed on the Nasdaq market in the United States, Inogen is followed by global investors looking for exposure to the respiratory devices and home oxygen therapy market. The company was founded in 2001 and built its business around a straightforward proposition: offer patients a more portable, lightweight and user-friendly alternative to traditional oxygen tanks and bulkier stationary systems. ([inogen.com](https://www.inogen.com/about-inogen/about-us/?utm_source=openai))
Inogen’s core business is the design, manufacture and commercialization of portable oxygen concentrators, along with stationary oxygen solutions and related respiratory products that support chronic respiratory patients. Its portfolio includes portable concentrators under the Inogen One and Rove families, as well as adjacent offerings such as CPAP masks and other respiratory-care products. The company sells through a mix of direct-to-consumer, home medical equipment partners, prescribers and distributors, with an established U.S. base and an expanding international footprint. ([inogen.com](https://www.inogen.com/about-inogen/about-us/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Inogen operates in a regulated and reimbursement-sensitive market where product portability, clinical differentiation, battery life, ease of use and access to reimbursement matter materially. Its historical edge comes from being one of the best-known names in portable oxygen concentrators, a niche where brand awareness and product credibility are important competitive assets. More recently, management has been working to diversify the portfolio beyond a single category and broaden the company’s addressable market in respiratory care. ([inogen.com](https://www.inogen.com/about-inogen/about-us/?utm_source=openai))
Recent developments are particularly relevant for investors. In 2025, Inogen announced a strategic collaboration with Jiangsu Yuwell Medical Equipment & Supply Co. to broaden its product portfolio, strengthen its innovation pipeline and accelerate entry into China; Yuwell also became a minority shareholder. The company also introduced new U.S. products, including the Voxi 5 stationary oxygen concentrator and Aurora CPAP masks, and began a limited U.S. market release of the Simeox airway clearance device. Most recently, Inogen reported improving profitability trends, including year-over-year revenue growth and positive adjusted EBITDA in 2025, while reiterating its 2026 guidance and continued focus on margin and cash-flow improvement. ([investor.inogen.com](https://investor.inogen.com/news-events/press-releases/detail/256/inogen-announces-fourth-quarter-and-full-year-2025?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
